Dasabuvir

Dasabuvir
Clinical data
Trade names	Exviera, Viekira Pak, Viekira XR
Other names	ABT-333
AHFS/Drugs.com	Viekira Pak Monograph; Dasabuvir UK Drug Information
MedlinePlus	a616040
License data	US DailyMed: Dasabuvir;
Routes of; administration	By mouth
ATC code	J05AP09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only co-packaged with ombitasvir/paritaprevir/ritonavir (Viekira Pak); EU: Rx-only;
Identifiers
	IUPAC name N-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide;
CAS Number	1132935-63-7;
PubChem CID	56640146;
DrugBank	DB09183;
ChemSpider	29776744;
UNII	DE54EQW8T1;
KEGG	D10553 ; as salt: D10581 ;
ChEBI	CHEBI:85182 ;
ChEMBL	ChEMBL3137312;
CompTox Dashboard (EPA)	DTXSID301025953 ;
ECHA InfoCard	100.232.246
Chemical and physical data
Formula	C26H27N3O5S
Molar mass	493.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)c1cc(cc(c1OC)c2ccc3cc(ccc3c2)NS(=O)(=O)C)n4ccc(=O)[nH]c4=O;
	InChI InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31); Key:NBRBXGKOEOGLOI-UHFFFAOYSA-N;

Dasabuvir, sold under the brand name Exviera, is an antiviral medication for the treatment of hepatitis C. It is often used together with the combination medication ombitasvir/paritaprevir/ritonavir specifically for hepatitis C virus (HCV) type 1. Ribavirin may also additionally be used. These combinations result in a cure in more than 90% of people. It is taken by mouth.

Common side effects include trouble sleeping, nausea, itchiness, and feeling tired. It is not recommended in those with liver failure but appears okay in people with kidney disease. While there is no evidence of harm if used during pregnancy, it has not been well studied. It should not be used with birth control pills that contain ethinylestradiol. Dasabuvir is in the HCV NS5B polymerase inhibitor class of medication.

Dasabuvir was approved for medical use in 2014. It is on the World Health Organization's List of Essential Medicines. In the United States, it is approved by the Food and Drug Administration (FDA) only for use in combination with ombitasvir/paritaprevir/ritonavir. As of 2015, the ability to get these medications in many areas of the world is poor.